ZTS - Largest Animal Health Firm Zoetis Hit With European Probe Over Possible Breach of Competition Rules Related To Dog Pain Medicine | Benzinga
The European Commission announced on Tuesday that it has initiated an investigation into whether Zoetis Inc (NYSE: ZTS hindered the market launch of a competing pain medication for dogs.
Zoetis’ Librela is the first and only monoclonal antibody medicine approved in Europe to treat pain associated with osteoarthritis in dogs.
The medicine is administered monthly and offers a novel pain relief option, particularly relevant for older dogs.
The European Commission said that Zoetis, while working on Librela, also acquired another pain relief product in ...